GLP-1 receptor agonists: antidiabetic agents with antiatherogenic effect

Česká verzia

Authors: Ivan Tkáč
Authors place of work: Excelentný tím pre výskum aterosklerózy (EXTASY), IV. interná klinika UPJŠ LF a UN LP Košice
Published in the journal: AtheroRev 2020; 5(3): 181-184
Category: Clinical Studies

Summary

GLP-1 receptor agonists (GLP1 RA) have been used in the treatment of type 2 diabetes for the past 15 years. In the last five years, several randomized clinical trials with drugs of this group – liraglutide, semaglutide, albiglutide and dulaglutide – have demonstrated their ability to prevent major cardiovascular events. Therefore, some international recommendations list them as the drugs of the first choice in the treatment of patients with type 2 diabetes and proven clinical or subclinical atherosclerosis.

Keywords:

cardiovascular prevention – GLP-1 receptor agonists – treatment of type 2 diabetes

Zdroje

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 854–865. Erratum in Lancet 1998; 352(9139): 1558.
Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–1289. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67528–9>.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 2007; 356(24): 2457–2471. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa072761>.
Home PD, Pocock SJ, Beck-Nielsen H et al. [RECORD Study Team]. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125–2135. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60953–3>.
Verma S, McMurray JJ. SGLT2 inhibitors and mechanism of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018; 61(10): 2108–2117. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4670–7>.
Nauck MA, Meier JJ. Incretin hormones. Their role in health and disease. Diabetes Obes Metab 2018; 20(Suppl 1): S5-S21. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13129>.
Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia 2019; 62(3): 357–369. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4801–1>.
Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23): 2247–2257. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1509225>.
Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.
Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834–1844. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607141>.
Holman RR, Bethel MB, Mentz RJ et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228–1239. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1612917>.
Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519–1529. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32261-X>.
Gerstein HC, Calhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121–130. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)31149–3>.
Husain M, Birkenfeld A, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841–851. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1901118>.
Drucker DJ. The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications. Diabetes 2018; 67(9): 1710–1719. Dostupné z DOI: Dostupné z DOI: <http://dx.doi.org/10.2337/dbi18–0008>.
Kristensen SL, Rørth R, Jhund PS et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancets Diabetes Endocrinol 2019; 7(10):776–785. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(19)30249–9>.
Buse JB, Wexler DJ, Tsapas A et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63(2): 221–228. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–019–05039-w>.